EGFR and non-small cell lung carcinoma: Furthermore, a phase II study of toripalimab combined with chemotherapy has demonstrated a higher ORR of 50% and longer median PFS of 7 months in EGFR-mutant advanced NSCLC patients who failed to prior EGFR TKIs therapies, which provides a novel choice for such patients (101).